8-K/A: Aditxt Amends Agreement to Acquire Appili Therapeutics, Extends Outside Date to November 19, 2024

Aditxt, Inc. has further amended its agreement to acquire Appili Therapeutics, extending the outside date for the transaction to November 19, 2024, and providing updated financial statements.

Summary

• Aditxt, Inc. is in the process of acquiring Appili Therapeutics through its subsidiary Adivir, Inc.
• The acquisition is structured as a statutory plan of arrangement under the Canada Business Corporation Act.
• The agreement has been amended multiple times, with the latest amendment extending the outside date to November 19, 2024.
• The deal is contingent on Aditxt completing financing by October 18, 2024.
• Appili must hold a shareholder meeting no later than November 6, 2024, but not before 50 days after Aditxt provides complete financial disclosures.
• A mutual waiver was agreed upon, extending any termination rights until December 15, 2024.
• Adivir will pay Appili a $115,000 waiver fee.
• The board of directors of Adivir will be reconstituted after the acquisition.
• This amendment includes the required historical condensed consolidated financial statements of Appili as of and for September 30, 2024 and 2023, and pro forma financial information.
• The pro forma financial information is for informational purposes only and does not represent actual or future results.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the repeated delays, the need for additional financing, and Appili's poor financial health. While the acquisition is still progressing, the challenges and uncertainties are significant.

Positives

• The acquisition of Appili by Aditxt is still progressing, despite multiple amendments and extensions.
• The mutual waiver provides additional time for the transaction to be completed.
• The inclusion of Appili's financial statements provides transparency for investors.
• The reconstitution of Adivir's board of directors provides clarity on the future leadership of the subsidiary.

Negatives

• The repeated amendments and extensions of the agreement suggest potential challenges in completing the acquisition.
• The need for Aditxt to secure financing by October 18, 2024, introduces uncertainty.
• Appili's financial statements show a net loss of $2,328,405 for the six months ended September 30, 2024, and an accumulated deficit of $71,421,521.

Risks

• The acquisition is contingent on Aditxt securing financing, which may not be successful.
• The transaction could be terminated if financing is not completed by the deadline.
• Appili's financial condition raises concerns about its ability to continue as a going concern.
• The pro forma financial information is not indicative of future results.
• The transaction is subject to various approvals and conditions, which may not be met.

Future Outlook

The document states that the pro forma financial information is for informational purposes only and does not represent the actual results of operations that the Company and Appili would have achieved had the entities been combined at and during the period presented in the pro forma financial information, and is not intended to project the future results of operations that the combined company may achieve following the transactions.

Industry Context

This announcement reflects ongoing consolidation activity within the biotechnology sector, where companies often seek to expand their pipelines and market reach through acquisitions. The challenges faced by Aditxt in securing financing and meeting deadlines are not uncommon in such transactions.

Comparison to Industry Standards

• The financial results of Appili, with a significant accumulated deficit and ongoing losses, are not uncommon for early-stage biotech companies focused on research and development.
• The need for multiple amendments and extensions in the acquisition agreement is not unusual in complex transactions, particularly those involving cross-border deals and financing requirements.
• The pro forma financial statements are a standard practice in merger and acquisition announcements, providing investors with a hypothetical view of the combined entity's financials.
• The inclusion of detailed financial statements and pro forma information is consistent with industry best practices for transparency in M&A transactions.

Management Changes

Related Party Transactions

• Appili obtained an unsecured bridge loan from Bloom Burton, a related party.

Stakeholder Impact

• Shareholders of Aditxt and Appili are impacted by the potential acquisition and its terms.
• Employees of both companies may be affected by the merger.
• Creditors of Appili are impacted by the assumption of liabilities by Aditxt.
• Customers and suppliers of both companies may experience changes due to the acquisition.

Next Steps

• Aditxt needs to complete its financing by October 18, 2024.
• Appili must convene its shareholder meeting by November 6, 2024.
• The parties must complete the acquisition by the new outside date of November 19, 2024, or the extended termination date of December 15, 2024.
• The board of directors of Adivir will be reconstituted after the acquisition.

Key Dates

Keywords

acquisition, Aditxt, Appili Therapeutics, merger, financing, financial statements, pro forma, arrangement agreement, amendment, Adivir